GlobalData on MSN17h
Nektar completes enrolment in trial of rezpegaldesleukin for alopecia areata
Nektar Therapeutics has concluded target enrolment in the Phase IIb REZOLVE-AA trial of its investigational biologic therapy, ...
William Blair Keeps Their Buy Rating on Cardiff Oncology (CRDF)
William Blair analyst Andy Hsieh reiterated a Buy rating on Cardiff Oncology (CRDF – Research Report) today. The company’s shares closed today ...
William Blair Sticks to Their Hold Rating for Altimmune (ALT)
In a report released today, Andy Hsieh from William Blair maintained a Hold rating on Altimmune (ALT – Research Report). The company’s shares ...